# An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Source: https://onco.cc/trials/nct06281847/  
OnCo record `nct06281847` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CCTx-001 run by Advesya SAS, not yet recruiting.

## Summary

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia is a phase 1/2 interventional study registered as NCT06281847 by Advesya SAS, with 143 participants planned, started 2025-12. Conditions recorded: Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory. Interventions recorded: CCTx-001.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06281847
- Phase: 1/2
- Setting: An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
- Sponsor: Advesya SAS
- Enrolled: 143

## Sources

- ClinicalTrials.gov NCT06281847: https://clinicaltrials.gov/study/NCT06281847

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [CCTx-001](https://onco.cc/drugs/cctx-001/)
- companies: [Advesya](https://onco.cc/companies/advesya/)

---
JSON: https://onco.cc/api/v1/entities/nct06281847.json